Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.
Trial results show setrusumab reduces the incidence of fracture and increases bone density and formation. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Zacks Investment Research on MSN
Rare, MREO tank as osteogenesis study fails to meet primary endpoint
Shares of Ultragenyx Pharmaceutical RARE and Mereo BioPharma MREO plunged 42.3% and 87.6%, respectively, on Dec. 29 after the ...
The global Phase 3 Cosmic study evaluated the effect of setrusumab on reduction in annualized fracture rate in patients aged 2 to <7 years compared to bisphosphonates. The Cosmic study has enrolled 69 ...
A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...
Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback